The current state of proteomics in GI oncology

Ying Lin, William S. Dynan, Jeffrey R Lee, Zhao Hua Zhu, Robert R. Schade

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

Original languageEnglish (US)
Pages (from-to)431-457
Number of pages27
JournalDigestive Diseases and Sciences
Volume54
Issue number3
DOIs
StatePublished - Mar 2009

Keywords

  • Biomarker discovery
  • Clinical proteomics
  • Gastrointestinal oncology
  • Mass spectrometry

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Fingerprint Dive into the research topics of 'The current state of proteomics in GI oncology'. Together they form a unique fingerprint.

  • Cite this

    Lin, Y., Dynan, W. S., Lee, J. R., Zhu, Z. H., & Schade, R. R. (2009). The current state of proteomics in GI oncology. Digestive Diseases and Sciences, 54(3), 431-457. https://doi.org/10.1007/s10620-008-0656-5